The UW-Milwaukee Research Foundation and MPP Group LLC have announced the completion of a license agreement for a series of compounds that may be useful in the treatment and control of alcohol addiction.
The family of compounds licensed by MPP Group LLC, a Wauwatosa-based biopharma company, appears to interact with certain neurotransmitters in the brain to block the euphoric effects of alcohol without inducing anxiety or sedation.
The compounds, developed by James Cook, UWM chemistry professor, also may be useful in treating other addictive behaviors or disorders. MPP Group and its partners and collaborators will develop the compounds to produce an FDA-approved therapeutic agent for the treatment of alcohol addiction, which affects about 17 million Americans.
See release: http://www.wisbusiness.com/index.iml?Article=129168